Precision Biosciences (DTIL) Total Current Liabilities (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Total Current Liabilities data on file, last reported at $7.8 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $7.8 million, down 37.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.8 million (down 37.42% YoY), and the FY2025 annual result was $8.9 million, down 40.5% from the prior year.
• Total Current Liabilities eased to $7.8 million in Q1 2026 per DTIL's latest filing, from $8.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $61.1 million in Q3 2022 and troughed at $7.8 million in Q1 2026.
• A 5-year average of $32.9 million and a median of $33.0 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities jumped 67.64% in 2022, then slumped 76.33% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $59.7 million in 2022, then retreated by 16.22% to $50.0 million in 2023, then tumbled by 70.03% to $15.0 million in 2024, then tumbled by 40.5% to $8.9 million in 2025, then fell by 12.99% to $7.8 million in 2026.
• Business Quant data shows DTIL's Total Current Liabilities at $7.8 million in Q1 2026, $8.9 million in Q4 2025, and $15.0 million in Q3 2025.